Sensei Biotherapeutics, Inc. (SNSE)
NASDAQ: SNSE · Real-Time Price · USD
29.90
-2.38 (-7.37%)
At close: Mar 16, 2026, 4:00 PM EDT
29.89
-0.01 (-0.03%)
Pre-market: Mar 17, 2026, 9:27 AM EDT
Sensei Biotherapeutics Employees
As of December 31, 2024, Sensei Biotherapeutics had 15 total employees, including 14 full-time and 1 part-time employees. The number of employees decreased by 13 or -46.43% compared to the previous year.
Employees
15
Change (1Y)
-13
Growth (1Y)
-46.43%
Revenue / Employee
n/a
Profits / Employee
-$1,609,200
Market Cap
37.72M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 15 | -13 | -46.43% | 14 | 1 |
| Dec 31, 2023 | 28 | 0 | - | 27 | 1 |
| Dec 31, 2022 | 28 | -28 | -50.00% | 28 | 0 |
| Dec 31, 2021 | 56 | 24 | 75.00% | 56 | 0 |
| Dec 31, 2020 | 32 | - | - | 30 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 123 |
| Werewolf Therapeutics | 39 |
| Palatin Technologies | 29 |
| Jasper Therapeutics | 27 |
| Actinium Pharmaceuticals | 25 |
| INmune Bio | 22 |
| Veru Inc. | 20 |
| CervoMed | 15 |
SNSE News
- 3 hours ago - Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 20 days ago - Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 27 days ago - Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - Business Wire
- 2 months ago - Egle Therapeutics Appoints John Celebi as Chief Executive Officer - GlobeNewsWire
- 4 months ago - Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value - GlobeNewsWire
- 5 months ago - Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025 - GlobeNewsWire
- 6 months ago - Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025 - GlobeNewsWire